PIK3CB and neoplasm: An in vitro study of the dual PI3K/mTOR inhibitors, gedatolisib and PF-04691502, tested on 12 canine tumour cell lines (of 6 tumour types), found that gedatolisib decreased cell viability in a dose-dependent manner in all cell lines; however, some were more sensitive than others [227].